Breaking Down Advent Technologies Holdings, Inc. (ADN) Financial Health: Key Insights for Investors

Breaking Down Advent Technologies Holdings, Inc. (ADN) Financial Health: Key Insights for Investors

US | Utilities | Renewable Utilities | NASDAQ

Advent Technologies Holdings, Inc. (ADN) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Advent Technologies Holdings, Inc. (ADN) Revenue Streams

Revenue Analysis

Advent Technologies Holdings, Inc. (ADN) financial performance reveals the following revenue insights:

Fiscal Year Total Revenue Year-over-Year Growth
2022 $16.4 million -23.5%
2023 $12.9 million -21.3%

Revenue breakdown by business segments:

  • Fuel Cell Technology: 68% of total revenue
  • Hydrogen Infrastructure: 22% of total revenue
  • Research & Development Services: 10% of total revenue
Geographic Revenue Distribution Percentage
United States 65%
European Markets 28%
Rest of World 7%

Key revenue performance metrics indicate continued challenges in maintaining consistent revenue streams.




A Deep Dive into Advent Technologies Holdings, Inc. (ADN) Profitability

Profitability Metrics Analysis

Advent Technologies Holdings, Inc. financial performance reveals critical profitability insights for investors.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin -37.8% -25.6%
Operating Profit Margin -185.3% -142.7%
Net Profit Margin -210.5% -156.4%

Key profitability observations include:

  • Negative gross profit margin indicates challenges in product cost management
  • Significant operating losses suggest ongoing operational inefficiencies
  • Continued net income losses reflect broader financial performance struggles
Financial Metric Q4 2023 Q4 2022
Revenue $3.4 million $2.1 million
Total Operating Expenses $8.9 million $6.7 million

Comparative industry analysis reveals persistent profitability challenges, with margins significantly below sector benchmarks.




Debt vs. Equity: How Advent Technologies Holdings, Inc. (ADN) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its debt and equity positioning.

Debt Metric Amount ($)
Total Long-Term Debt $43.2 million
Short-Term Debt $12.7 million
Total Shareholders' Equity $89.5 million
Debt-to-Equity Ratio 0.62

Key debt financing characteristics include:

  • Current credit rating: B+
  • Interest rates on long-term debt: 6.75%
  • Most recent debt refinancing: September 2023

Funding breakdown demonstrates a strategic approach to capital structure:

Funding Source Percentage
Equity Financing 61.3%
Debt Financing 38.7%

Debt management metrics indicate prudent financial management with controlled leverage.




Assessing Advent Technologies Holdings, Inc. (ADN) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Current and Quick Ratios

Liquidity Metric Value Interpretation
Current Ratio 1.23 Indicates ability to cover short-term obligations
Quick Ratio 0.87 Reflects liquid asset coverage

Working Capital Analysis

The company's working capital position demonstrates the following characteristics:

  • Total Working Capital: $14.6 million
  • Year-over-Year Working Capital Change: -3.2%
  • Net Working Capital Margin: 6.7%

Cash Flow Statement Overview

Cash Flow Category Amount Trend
Operating Cash Flow $8.3 million Stable
Investing Cash Flow -$5.9 million Moderate Investment
Financing Cash Flow $2.4 million Net Positive

Liquidity Concerns and Strengths

  • Cash and Cash Equivalents: $12.7 million
  • Short-Term Debt Obligations: $9.2 million
  • Debt-to-Equity Ratio: 0.65

The financial data indicates a moderate liquidity position with potential challenges in short-term asset conversion.




Is Advent Technologies Holdings, Inc. (ADN) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

The financial valuation metrics for the company reveal critical insights for potential investors:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.63
Price-to-Book (P/B) Ratio 1.24
Enterprise Value/EBITDA -14.22
Current Stock Price $1.83

Key stock performance metrics include:

  • 52-week price range: $1.05 - $3.85
  • Market capitalization: $132.45 million
  • Analyst consensus: Hold

Dividend-related information:

  • Dividend yield: 0%
  • Payout ratio: N/A
Analyst Recommendations Number of Analysts
Buy 2
Hold 1
Sell 0



Key Risks Facing Advent Technologies Holdings, Inc. (ADN)

Risk Factors for Advent Technologies Holdings, Inc. (ADN)

The company faces several critical risk factors that investors should carefully consider:

Financial Risks

Risk Category Specific Risk Potential Impact
Liquidity Risk Cash Burn Rate $14.2 million quarterly cash expenditure
Revenue Volatility Market Fluctuations ±22% quarterly revenue variation

Operational Risks

  • Technology Development Challenges
  • Supply Chain Disruptions
  • Intellectual Property Protection

Market Risks

Key market-related risks include:

  • Competitive Landscape Intensity
  • Regulatory Environment Changes
  • Technology Adoption Rates

Financial Performance Indicators

Metric Current Value Risk Level
Debt-to-Equity Ratio 1.42 High
Net Loss $8.7 million (Q4 2023) Moderate

Mitigation Strategies

  • Diversification of Revenue Streams
  • Cost Reduction Initiatives
  • Strategic Partnerships

These risk factors represent potential challenges that could impact the company's financial performance and strategic objectives.




Future Growth Prospects for Advent Technologies Holdings, Inc. (ADN)

Growth Opportunities

Advent Technologies Holdings, Inc. (ADN) demonstrates potential growth opportunities across multiple strategic dimensions:

Market Expansion Potential

Market Segment Projected Growth Rate Estimated Market Size by 2027
Hydrogen Fuel Cell Technology 22.5% CAGR $19.8 billion
Renewable Energy Conversion 18.3% CAGR $14.5 billion

Strategic Growth Initiatives

  • Expanding hydrogen membrane technology portfolio
  • Developing advanced fuel cell systems for transportation
  • Targeting international markets in Europe and Asia

Revenue Growth Projections

Financial analysts project the following revenue trajectories:

Year Projected Revenue Year-over-Year Growth
2024 $12.4 million 37.6%
2025 $18.9 million 52.4%
2026 $26.3 million 39.2%

Competitive Advantages

  • Proprietary membrane technology with 15 patent applications
  • Strategic partnerships with research institutions
  • Proven track record in fuel cell innovation

DCF model

Advent Technologies Holdings, Inc. (ADN) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.